{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T04:27:27Z","timestamp":1780374447147,"version":"3.54.1"},"reference-count":44,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Tumori"],"published-print":{"date-parts":[[2016,7]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p> Single nucleotide polymorphisms (SNPs) in the DNA repair genes are believed to contribute to the clinical outcome of patients receiving platinum-based chemotherapy. We investigated the impact of 2 SNPs of excision repair cross-complementation group 1 and 2 of xeroderma pigmentosum complementation group G on the outcome in patients with non-small-cell lung cancer (NSCLC) treated with platinum-based chemotherapy. <\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p> Between October 2007 and March 2012, we collected 374 blood samples from consecutive patients registered in the TAILOR trial. Four SNPs (rs11615, rs3212986, rs17655, rs1047768) were genotyped using real-time polymerase chain reaction. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p> The rs11615 polymorphism was associated with histotype (p = 0.0123). No other correlations were found with clinical variables or with EGFR or KRAS mutational status. None of the SNPs had any impact on overall survival or progression-free survival. <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p> The findings suggest that the investigated SNPs do not make any significant contribution to the outcome of NSCLC. <\/jats:p><\/jats:sec>","DOI":"10.5301\/tj.5000526","type":"journal-article","created":{"date-parts":[[2016,7,11]],"date-time":"2016-07-11T08:19:50Z","timestamp":1468225190000},"page":"367-375","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["DNA Repair Gene Polymorphisms in Non-Small-Cell Lung Cancer Patients Treated with First-Line Platinum-Containing Chemotherapy"],"prefix":"10.1177","volume":"102","author":[{"given":"Eliana","family":"Rulli","sequence":"first","affiliation":[{"name":"Clinical Research Methodology Laboratory, Oncology Department, IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Milan - Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirko","family":"Marabese","sequence":"additional","affiliation":[{"name":"Molecular Genetics Unit, Oncology Department, IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Milan - Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheila","family":"Piva","sequence":"additional","affiliation":[{"name":"Oncology Department, Ospedale Fatebenefratelli e Oftalmico, Milan - Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Bonomi","sequence":"additional","affiliation":[{"name":"Oncology Department, Ospedale Papa Giovanni XXIII, Bergamo - Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Caiola","sequence":"additional","affiliation":[{"name":"Molecular Genetics Unit, Oncology Department, IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Milan - Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Ganzinelli","sequence":"additional","affiliation":[{"name":"Thoracic Unit, Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan - Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2016,7,7]]},"reference":[{"key":"bibr1-tj.5000526","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2005-0158OE"},{"key":"bibr2-tj.5000526","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccm.2011.09.001"},{"key":"bibr3-tj.5000526","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Non-small cell lung cancer Version 1. 2015 (2014) www.nccn.org. last accessed on 6 December 2014."},{"issue":"1","key":"bibr4-tj.5000526","first-page":"36","volume":"4","author":"Chan BA","year":"2015","journal-title":"Transl Lung Cancer Res"},{"key":"bibr5-tj.5000526","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2014.74"},{"key":"bibr6-tj.5000526","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.33.15_suppl.8035"},{"key":"bibr7-tj.5000526","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200694"},{"key":"bibr8-tj.5000526","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.8049"},{"key":"bibr9-tj.5000526","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(01)00454-5"},{"key":"bibr10-tj.5000526","doi-asserted-by":"publisher","DOI":"10.1111\/1440-1681.12282"},{"key":"bibr11-tj.5000526","doi-asserted-by":"publisher","DOI":"10.1186\/s12929-015-0185-4"},{"key":"bibr12-tj.5000526","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.4610"},{"key":"bibr13-tj.5000526","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0025164"},{"issue":"4","key":"bibr14-tj.5000526","first-page":"1318","volume":"10","author":"Rosell R","year":"2004","journal-title":"Ribonucleotide reductase messenger RNA expression and survival in gemcitabine\/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res"},{"key":"bibr15-tj.5000526","doi-asserted-by":"publisher","DOI":"10.1016\/j.cancergencyto.2005.03.008"},{"key":"bibr16-tj.5000526","doi-asserted-by":"publisher","DOI":"10.5761\/atcs.oa.09.01526"},{"key":"bibr17-tj.5000526","doi-asserted-by":"publisher","DOI":"10.3816\/CLC.2009.n.007"},{"key":"bibr18-tj.5000526","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-2664"},{"key":"bibr19-tj.5000526","doi-asserted-by":"publisher","DOI":"10.1007\/s13277-014-1615-8"},{"key":"bibr20-tj.5000526","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2013.05.021"},{"key":"bibr21-tj.5000526","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh319"},{"key":"bibr22-tj.5000526","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26562"},{"key":"bibr23-tj.5000526","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2010.10.011"},{"key":"bibr24-tj.5000526","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2013.08.018"},{"key":"bibr25-tj.5000526","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-010-9443-1"},{"key":"bibr26-tj.5000526","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-0247"},{"key":"bibr27-tj.5000526","doi-asserted-by":"publisher","DOI":"10.3816\/CLC.2009.n.015"},{"key":"bibr28-tj.5000526","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2011.03.023"},{"key":"bibr29-tj.5000526","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.274.26.18759"},{"key":"bibr30-tj.5000526","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2008.11.014"},{"key":"bibr31-tj.5000526","doi-asserted-by":"publisher","DOI":"10.4238\/2014.March.31.13"},{"key":"bibr32-tj.5000526","doi-asserted-by":"publisher","DOI":"10.1007\/s13277-014-1732-4"},{"issue":"10","key":"bibr33-tj.5000526","first-page":"981","volume":"14","author":"Garassino MC","year":"2013","journal-title":"Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol"},{"key":"bibr34-tj.5000526","doi-asserted-by":"publisher","DOI":"10.1038\/srep16331"},{"key":"bibr35-tj.5000526","doi-asserted-by":"publisher","DOI":"10.1038\/tpj.2011.50"},{"key":"bibr36-tj.5000526","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.5607"},{"key":"bibr37-tj.5000526","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0802714"},{"key":"bibr38-tj.5000526","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2014.10.003"},{"key":"bibr39-tj.5000526","doi-asserted-by":"publisher","DOI":"10.1038\/tpj.2014.32"},{"key":"bibr40-tj.5000526","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2010.10.011"},{"issue":"8","key":"bibr41-tj.5000526","first-page":"1695","volume":"108","author":"Tiseo M","year":"2013","journal-title":"ERCC1\/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin. Br J Cancer"},{"key":"bibr42-tj.5000526","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3182307e1f"},{"key":"bibr43-tj.5000526","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2011.384"},{"key":"bibr44-tj.5000526","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-011-1632-x"}],"container-title":["Tumori Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.5301\/tj.5000526","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.5301\/tj.5000526","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.5301\/tj.5000526","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T22:02:24Z","timestamp":1741039344000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.5301\/tj.5000526"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["10.5301\/tj.5000526"],"URL":"https:\/\/doi.org\/10.5301\/tj.5000526","relation":{},"ISSN":["0300-8916","2038-2529"],"issn-type":[{"value":"0300-8916","type":"print"},{"value":"2038-2529","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7]]}}}